Labs / ADME, DMPK & toxicology

Manhattan BioSolutions
New York, NY, United States · manhattanbiosolutions.com
Manhattan BioSolutions develops precision biologic therapies, with a focus on next-generation antibody-drug conjugates for advanced cancers. It collaborates with academic researchers and other partners and is based in New York City.
Their website has a general contact form; we send your quote request through it.
What they offer
Antibody-drug conjugate (ADC) platform development
Develops next-generation ADCs with custom linker chemistry and payload design for targeted cancer therapy.
Legumain-cleavable linker-payload systems
Creates linker systems that remain stable in circulation and activate in the tumor microenvironment for localized payload release.
TOP1i ADC payload development
Optimizes topoisomerase I inhibitor payloads derived from exatecan for ADC applications.
Taxoid (TxD) ADC payload development
Advances taxoid-based payloads for antibody-drug conjugates targeting solid tumors.
Pan-RNA degrader technology
Develops pan-RNA degrader technologies intended to selectively degrade RNA in tumors and their microenvironment.
Antibody engineering and bioconjugation
Combines antibody engineering, linker chemistry, and bioconjugation to build targeted biologic agents.
What they work on
- Modalities
- Antibody, ADC, Peptide
- Species and models
- solid tumor xenograft models, ovarian cancer models, prostate cancer models, non-small cell lung cancer models, colon cancer models
- Assays and studies
- high throughput FRET-based screen
- Therapeutic areas
- oncology, advanced cancers, solid tumors, pediatric cancers, inflammatory responses, age-related diseases
- Sites
- New York City, United States
Similar labs. Aurigene Pharmaceutical Services, Sparx BIO, Bioneeds, Sai Life
Found in a contract services directory. Listing built from manhattanbiosolutions.com. Work here? Claim this listing.